- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:47 | Baidu Wenku, Baidu Drive Launch GenFlow 2.0, Universal Agent Across All Platforms | 6 | AASTOCKS | ||
| 10:12 | Baidu.Inc: Baidu Wenku and Netdisk Launch GenFlow 2.0, Deploying Over 100 AI Agents Simultaneously | 197 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- Baidu Wenku and Netdisk, Baidu's AI-powered productivity apps, have introduced GenFlow 2.0, a general AI agent featuring more than 100 parallel agents... ► Artikel lesen | |
| 08:34 | Genflow: Gentherapie-Studie zur Langlebigkeit bei Hunden zeigt keine Nebenwirkungen | 6 | Investing.com Deutsch | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08:30 | Genflow reports no adverse effects in dog longevity gene therapy trial | 2 | Investing.com | ||
| 08:02 | Genflow Biosciences PLC Announces Company Update on Dog Trials | 114 | ACCESS Newswire | Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported LONDON, UK / ACCESS Newswire / August 18, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF)... ► Artikel lesen | |
| 08:00 | Genflow Biosciences - Company Update on Dog Trials | 1 | RNS | ||
| 24.07. | Genflow Biosciences advances clinical programs for longevity therapies | 2 | Investing.com | ||
| 24.07. | Genflow Biosciences treibt klinische Programme für Langlebigkeits-Therapien voran | 1 | Investing.com Deutsch | ||
| 24.07. | Genflow Biosciences PLC Announces Clinical Readiness Acceleration | 173 | ACCESS Newswire | Clinical Readiness Accelerates Across Genflow Biosciences Lead Programs LONDON, UK / ACCESS Newswire / July 24, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the... ► Artikel lesen | |
| 24.07. | Genflow Biosciences - Clinical Readiness Acceleration | 2 | RNS | ||
| 17.07. | Genflow Biosciences PLC: Genflow Confirms Progression of Grant | 133 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 17.07. | Genflow Biosciences - Genflow Confirms Progression of Grant | - | RNS | ||
| 17.06. | Genflow Biosciences PLC Announces Corporate Update | 279 | ACCESS Newswire | Genflow Biosciences Provides Half Year Corporate Update on SIRT6 Programs, IP Progress and Strategic Partnerships LONDON, UK / ACCESS Newswire / June 17, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF)... ► Artikel lesen | |
| 17.06. | Genflow Biosciences - Corporate Update | 1 | RNS | ||
| 12.06. | Genflow Biosciences - Result of AGM | 4 | RNS | ||
| 30.05. | Genflow Biosciences - Total Voting Rights | - | RNS | ||
| 28.05. | Genflow Biosciences unterzeichnet F&E-Abkommen mit belgischer CER Groupe | 1 | Investing.com Deutsch | ||
| 28.05. | Genflow Biosciences inks R&D pact with Belgian CER Groupe | 1 | Investing.com | ||
| 28.05. | Genflow Biosciences PLC: Genflow Biosciences and CER Sign Master Service Agreement to Strengthen Long-Term R&D Collaboration | 368 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / May 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce... ► Artikel lesen | |
| 28.05. | Genflow Biosciences - Genflow Signs Master Services Agreement | - | RNS |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 12,380 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | 0,00 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| VALNEVA | 5,075 | +6,48 % | AKTIE IM FOKUS: Valneva schnellen hoch - Halbjahreszahlen treiben an | PARIS (dpa-AFX) - Robuste Geschäftszahlen zum ersten Halbjahr haben die Aktien von Valneva am Dienstag angetrieben. Die Papiere des französischen Impfstoffherstellers schnellten im frühen Handel um... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,765 | 0,00 % | Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid | ||
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| IMMUNOME | 10,280 | 0,00 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| LENZ THERAPEUTICS | 37,870 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| EVOTEC | 6,264 | -1,45 % | EQS-News: Evotec SE gibt Ergebnisse für das erste Halbjahr 2025 bekannt: Deutliche Fortschritte bei Strategieumsetzung | EQS-News: Evotec SE
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
Evotec SE gibt Ergebnisse für das erste Halbjahr 2025 bekannt: Deutliche Fortschritte bei Strategieumsetzung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | 0,00 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen | |
| ARCELLX | 74,01 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,990 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,007 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.